The assessment of breast cancer response to neoadjuvant chemotherapy: Comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography

Acta Radiologica

Volumn 52, Issue 1, 2011, Pages 21-28

  Park, Jeong Seon ^a,b   Moon, Woo Kyung ^a   Lyou, Chae Yeon ^a   Cho, Nariya ^a   Kang, Keon Wook ^a   Chung, June Key ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Hanyang University   (South Korea)

Author keywords

Breast neoplasms; Magnetic resonance imaging; Neoadjuvant chemotherapy; Positron emission tomography

Indexed keywords

18-F-FLUORODEOXYGLUCOSE; BREAST CANCER; BREAST NEOPLASM; COMPLETE RESPONSE; FLUORODEOXYGLUCOSE-POSITRON EMISSION TOMOGRAPHIES; IMAGING MODALITY; LOCALLY ADVANCED BREAST CANCER; MCNEMAR; NEGATIVE PREDICTIVE VALUE; PARTIAL RESPONSE; PATHOLOGIC COMPLETE RESPONSE (PCR); PATHOLOGIC RESPONSE; PEARSON'S CORRELATION COEFFICIENTS; POSITIVE PREDICTIVE VALUES; REFERENCE STANDARD; STANDARD UPTAKE VALUES; TUMOR RESPONSE;

CHEMOTHERAPY; CORRELATION METHODS; DISEASES; ELECTRONS; MAGNETIC RESONANCE IMAGING; MEDICAL IMAGING; PATHOLOGY; POSITRONS; RATING; RESONANCE; TUMORS;

POSITRON EMISSION TOMOGRAPHY;

CONTRAST MEDIUM; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE; RADIOPHARMACEUTICAL AGENT;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST; BREAST TUMOR; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; HUMAN; IMAGE ENHANCEMENT; METHODOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVER VARIATION; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADULT; AGED; BREAST; BREAST NEOPLASMS; CONTRAST MEDIA; FEMALE; FLUORODEOXYGLUCOSE F18; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOADJUVANT THERAPY; OBSERVER VARIATION; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 79960088204     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.1258/ar.2010.100142     Document Type: Article

References (41)

1. Broet P, Scholl SM, de la Rochefordiere A, et al. Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial. Breast Cancer Res Treat 1999;58:151-6 (Pubitemid 30032487)
2. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-85 (Pubitemid 28363030)
3. Makris A, Powles TJ, Ashley SE, et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 1998;9:1179-84 (Pubitemid 28552806)
4. Mauriac L, MacGrogan G, Avril A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 1999;10:47-52 (Pubitemid 29090591)
5. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26:778-85 (Pubitemid 351264391)
6. Chagpar AB, Middleton LP, Sahin AA, et al. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg 2006;243:257-64 (Pubitemid 43185446)
7. Peintinger F, Kuerer HM, Anderson K, et al. Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Ann Surg Oncol 2006;13:1443-9 (Pubitemid 44749655)
8. Vinnicombe SJ, MacVicar AD, Guy RL, et al. Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation. Radiology 1996;198:333-40 (Pubitemid 26036832)
9. Fisher ER, Wang J, Bryant J, et al. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 2002;95:681-95 (Pubitemid 34845919)
10. Hylton N. MR imaging for assessment of breast cancer response to neoadjuvant chemotherapy. Magn Reson Imaging Clin N Am 2006;14:383-9, vii (Pubitemid 46053832)
11. McDermott GM, Welch A, Staff RT, et al. Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat 2007;102:75-84 (Pubitemid 46294965)
12. Partridge SC, Gibbs JE, Lu Y, et al. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. Am J Roentgenol 2002;179:1193-9 (Pubitemid 35204372)
13. Rosen EL, Blackwell KL, Baker JA, et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. Am J Roentgenol 2003;181:1275-82 (Pubitemid 37296403)
14. Londero V, Bazzocchi M, Del Frate C, et al. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol 2004;14:1371-9 (Pubitemid 39162217)
15. Yeh E, Slanetz P, Kopans DB, et al. Prospective comparison of mammography, sonography, and MRIinpatients undergoing neoadjuvant chemotherapy for palpable breast cancer. Am J Roentgenol 2005;184:868-77 (Pubitemid 43899515)
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16
17. Ah-See ML, Makris A, Taylor NJ, et al. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2008;14:6580-9
18. Lee KC, Moffat BA, Schott AF, et al. Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Clin Cancer Res 2007;13:443-50 (Pubitemid 46225348)
19. Pickles MD, Gibbs P, Lowry M, et al. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 2006;24:843-7 (Pubitemid 44205378)
20. Eubank WB, Mankoff DA, Schmiedl UP, et al. Imaging of oncologic patients: benefit of combined CT and FDG PET in the diagnosis of malignancy. Am J Roentgenol 1998;171:1103-10 (Pubitemid 28449985)
21. Rosen EL, Turkington TG, Soo MS, et al. Detection of primary breast carcinoma with a dedicated, large-field-of-view FDG PET mammography device: initial experience. Radiology 2005;234:527-34 (Pubitemid 40139925)
22. Pan L, Han Y, Sun X, et al. FDG-PET and other imaging modalities for the evaluation of breast cancer recurrence and metastases: a meta-analysis. J Cancer Res Clin Oncol 2010;136:1007-22
23. Kim SJ, Kim SK, Lee ES, et al. Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol 2004;15:1352-7 (Pubitemid 39295023)
24. Young H, Baum R, Cremerius U et al. Measurement of clinical subclinical tumour response using [18F]-fluorodeoxyglucose, positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773-82 (Pubitemid 29512308)
25. Chen X, Moore MO, Lehman CD, et al. Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy. Acad Radiol 2004;11:1115-24 (Pubitemid 39458085)
26. Dose-Schwarz J, Tiling R, Avril-Sassen S, et al. Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer. Br J Cancer 2010;102:35-41
27. Choi N, Han BK, Choe YH, et al. Three-phase dynamic breast magnetic resonance imaging with two-way subtraction. J Comput Assist Tomogr 2005;29:834-41 (Pubitemid 41689551)
28. American College of Radiology. Breast Imaging Reporting and Data System (BI-RADS) - MRI. 1st edn. Reston, VA: ACR, 2003
29. American College of Radiology Imaging Network website. Protocol-ACRIN 6657/CALGB 150007. See http://65.222.233.20/PROTOCOL SUMMARYTABLE/PROTOCOL6657/ tabid/147/Default.aspx
30. Gralow JR, Burstein HJ, Wood W, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 2008;26:814-9 (Pubitemid 351265335)
31. Sahoo S, Lester SC. Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting. Arch Pathol Lab Med 2009;133:633-42
32. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-9 (Pubitemid 29075229)
33. Marom EM, Munden RF, Truong MT, et al. Interobserver and intraobserver variability of standardized uptake value measurements in non-small-cell lung cancer. J Thorac Imaging 2006;21:205-12 (Pubitemid 44258947)
34. Orel S. Who should have breast magnetic resonance imaging evaluation? J Clin Oncol 2008;26:703-11 (Pubitemid 351264382)
35. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;30:96-102
36. Bassa P, Kim EE, Inoue T, et al. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 1996;37:931-8 (Pubitemid 126447124)
37. Burcombe RJ, Makris A, Pittam M, et al. Evaluation of good clinical response to neoadjuvant chemotherapy in primary breast cancer using [18F]-fluorodeoxyglucose positron emission tomography. Eur J Cancer 2002;38:375-9 (Pubitemid 34121965)
38. Akhurst T, Kates TJ, Mazumdar M, et al. Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol 2005;23:8713-6 (Pubitemid 46211515)
39. Heusner TA, Kuemmel S, Koeninger A, et al. Diagnostic value of diffusion-weighted magnetic resonance imaging (δWI) compared to FDG PET/CT for whole-body breast cancer staging. Eur J Nucl Med Mol Imaging 2010;37:1077-86
40. Berg WA, Gutierrez L, NessAiver MS, et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology 2004;233:830-49
41. Mann RM, Hoogeveen YL, Blickman JG, et al. MRI compared to conventional diagnostic work-up in the detection and evaluation of invasive lobular carcinoma of the breast: a review of existing literature. Breast Cancer Res Treat 2008;107:1-14 (Pubitemid 350179588)